Ferroptosis inhibitors and uses thereof

By discovering that the cell death mechanism caused by mitochondrial dysfunction is ferrodysfunction, and developing apomorphine derivatives as ferrodysfunction inhibitors, the problem of lack of effective treatment of diseases caused by mitochondrial dysfunction in the prior art has been solved, and related symptoms have been achieved , preventive or therapeutic effect of disease or disorder.

CN118251379BActive Publication Date: 2025-02-11JICHI MEDICAL UNIVERSITY
3 Cites 0 Cited by

Patent Information

Application Number
CN202280076182.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-11-15
Filing Date
2022-11-14
Publication Date
2025-02-11
Estimated Expiration
2042-11-14

Smart Images

  • Figure CN118251379B_ABST
    Figure CN118251379B_ABST
Patent Text Reader

Abstract

The present invention discloses the manifestation mechanism of symptoms, diseases or disorders caused by mitochondrial dysfunction, and provides a means for preventing or treating symptoms, diseases or disorders associated with the manifestation mechanism. One aspect of the present invention relates to a ferroptosis inhibitor, which contains a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof as an active ingredient. Another aspect of the present invention relates to a drug containing a ferroptosis inhibitor as an active ingredient for preventing or treating symptoms, diseases or disorders associated with ferroptosis. Another aspect of the present invention relates to a compound represented by formula (I-1) or a salt thereof, or a solvate thereof.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Electromagnetic wave phase amplitude generation device, electromagnetic wave phase amplitude generation method, and electromagnetic wave phase amplitude generation program

    JP2021185384A

  • Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor

    WO2019093379A1

  • Agent for improving mitochondrial dysfunction, preventative or therapeutic agent for diseases or symptoms caused by mitochondrial dysfunction, and applications therefor

    CN111556750A